- Home
- GRF vs HOWL Comparison
GRF vs HOWL Comparison
Compare GRF & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRF
- HOWL
- Stock Information
- Founded
- GRF 1989
- HOWL 2017
- Country
- GRF United States
- HOWL United States
- Employees
- GRF N/A
- HOWL N/A
- Industry
- GRF Finance/Investors Services
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- GRF Finance
- HOWL Health Care
- Exchange
- GRF Nasdaq
- HOWL Nasdaq
- Market Cap
- GRF 39.3M
- HOWL 47.1M
- IPO Year
- GRF N/A
- HOWL 2021
- Fundamental
- Price
- GRF $10.26
- HOWL $1.36
- Analyst Decision
- GRF
- HOWL Strong Buy
- Analyst Count
- GRF 0
- HOWL 3
- Target Price
- GRF N/A
- HOWL $8.33
- AVG Volume (30 Days)
- GRF 3.0K
- HOWL 554.2K
- Earning Date
- GRF 01-01-0001
- HOWL 08-07-2025
- Dividend Yield
- GRF 3.70%
- HOWL N/A
- EPS Growth
- GRF N/A
- HOWL N/A
- EPS
- GRF 1.16
- HOWL N/A
- Revenue
- GRF N/A
- HOWL $1,143,000.00
- Revenue This Year
- GRF N/A
- HOWL N/A
- Revenue Next Year
- GRF N/A
- HOWL N/A
- P/E Ratio
- GRF $8.15
- HOWL N/A
- Revenue Growth
- GRF N/A
- HOWL N/A
- 52 Week Low
- GRF $7.93
- HOWL $0.60
- 52 Week High
- GRF $10.19
- HOWL $4.18
- Technical
- Relative Strength Index (RSI)
- GRF 60.46
- HOWL 60.96
- Support Level
- GRF $9.86
- HOWL $1.25
- Resistance Level
- GRF $10.94
- HOWL $1.44
- Average True Range (ATR)
- GRF 0.12
- HOWL 0.10
- MACD
- GRF 0.04
- HOWL 0.02
- Stochastic Oscillator
- GRF 37.61
- HOWL 68.89
About GRF Eagle Capital Growth Fund Inc.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock by giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.